Compare TLS & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLS | ENTA |
|---|---|---|
| Founded | 1969 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.7M | 378.0M |
| IPO Year | 2020 | 2012 |
| Metric | TLS | ENTA |
|---|---|---|
| Price | $4.91 | $13.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $7.90 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 421.1K | 146.0K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.51 | 29.93 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $164,805,000.00 | $102,814,000.00 |
| Revenue This Year | $18.72 | $7.76 |
| Revenue Next Year | $14.62 | N/A |
| P/E Ratio | $155.33 | ★ N/A |
| Revenue Growth | ★ 52.21 | 16.48 |
| 52 Week Low | $2.37 | $6.45 |
| 52 Week High | $8.36 | $17.15 |
| Indicator | TLS | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.64 |
| Support Level | N/A | $11.92 |
| Resistance Level | N/A | $13.98 |
| Average True Range (ATR) | 0.00 | 0.61 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 0.00 | 23.35 |
Telos Corp offers technology solutions and services that empower and protect the world's security-conscious organizations. The company delivers efficient, adaptable, and secure solutions that protect people, organizations, and information across government and industry. The company conducts its business through two reportable and operating segments: Security Solutions and Secure Networks. The Security Solutions segment is focused on cybersecurity, cloud, and identity solutions, and secure messaging through Xacta, Telos AMHS, and Telos ID offerings. The Secure Networks segment provides secure networking architectures and solutions to customers through secure mobility solutions, network management, and defense services. The majority of revenue is from Secure Networks.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.